Venn Life Sciences Holdings PLC Euronext Growth - Schedule One (3489C)
June 14 2019 - 7:13AM
UK Regulatory
TIDMVENN
RNS Number : 3489C
Venn Life Sciences Holdings PLC
14 June 2019
Pre-Admission Announcement
Euronext Growth Schedule 1
Announcement to be made by the Euronext Growth Applicant
prior to admission in accordance with rule 2 of the Euronext
Growth Rules for Companies
--------------------------------------------------------------------------------------
All Applicants must complete the following
Company name
Venn Life Sciences Holdings plc
------------------------------------------------------------------- -----------------
Company registered address and if different, company trading
address (including postcodes)
Registered Office:
PO Box W1J 6BD, Berkley Square House, 2(nd) Floor, Mayfair,
London, W1J 8DJ
Trading Office:
19 Railway Road, Dalkey, Dublin, Ireland
--------------------------------------------------------------------------------------
Country of incorporation England and Wales
----------------------------------------------------------------- -------------------
Company website address containing all information required
by rule 26 in the Euronext Growth Rules for Companies
www.vennlifesciences.com/ and with effect from Admission,
www.openorphan.com
--------------------------------------------------------------------------------------
Company business (including main country of operation) or,
in the case of an investing company, details of its investing
strategy. If the admission is sought as a result of a reverse
takeover under rule 14 of the Euronext Growth Rules for
Companies, this should be stated
This is a reverse takeover under Rule 14.
Open Orphan is Clinical Research Organisation that specialises
in rare and orphan drugs. The headquarters are in Dublin,
Ireland and the company also has offices in France, the
Netherlands and Germany.
Details of securities to be admitted including any restrictions
as to transfer of securities (i.e. where known, number of
shares, nominal value and issue price to which it seeks
admission and the number and type to be held as treasury
shares):
Number of ordinary shares of 0.01 pence each in nominal
value ("Ordinary Shares") for which Admission will be sought:
253,493,259
Placing price per Ordinary Share: 5.6 pence
The are no restrictions as to the transferability of the
Ordinary Shares and no Ordinary Shares will be held in treasury.
Capital to be raised on admission (if applicable) and anticipated
market capitalisation on admission:
Capital to be raised on admission: GBP4.5m (EUR5.0m)
Anticipated market capitalisation on admission: GBP14.1m
(EUR15.8m)
Percentage of Euronext Growth securities not in public hands
on admission
Approximately 31.1%
-------------------------------------------------------------------------------------
Details of any other exchange or trading platform to which
the ex securities (or other securities of the company) are
or will be admitted or traded:
AIM
-------------------------------------------------------------------------------------
Full names and functions of directors and proposed directors
(underlining the first name by which each is known or including
any other name by which each is known):
Directors:
Brendan Buckley, Non-executive Chairman
Cathal Friel, Chief Executive Officer
Christian Milla, Chief Operating Officer
Tony Richardson, Corporate Development Officer
Michael Ryan, Senior non-executive Director
Proposed Director:
Maurice Treacy, Executive Director
-------------------------------------------------------------------------------------
Full names and holdings of significant shareholders, expressed
as a percentage of the issued share capital, before or after
admission (underlining the first name by which each is known
or including any other name by which each is known):
Before Admission
Name Number of Ordinary Percentage of issued
Shares share capital
Livingbridge VC LLP 13,081,337 18.3%
------------------- ---------------------
Kees Groen 4,780,320 6.7%
------------------- ---------------------
Calculus 4,696,461 6.6%
------------------- ---------------------
After Admission
Name Number of Ordinary Percentage of issued
Shares share capital
Cathal Friel 41,046,981 16.2%
------------------- ---------------------
Tony Richardson 16,313,388 6.4%
------------------- ---------------------
Livingbridge VC LLP 13,081,337 5.2%
------------------- ---------------------
Miton Asset Management 8,928,571 3.5%
------------------- ---------------------
Crux Asset Management 8,928,571 3.5%
------------------- ---------------------
Brendan Buckley 7.845,860 3.1%
------------------- ---------------------
-----------------------------------------------------------------------------------------
Names of all persons to be disclosed in accordance with
schedule two, paragraph (h) of the Euronext Growth Rules
for Companies:
n/a
-----------------------------------------------------------------------------------------
i anticipated accounting reference date :
31 December
ii date to which the main financial information
in the admission document has been prepared:
31 December 2018
iii. dates by which it must publish its first
three reports pursuant to Rules 18 and 19
in the Euronext Growth Rules for Companies:
30 June 2019 due September 2019, 31 December
2019 due 30 June 2020, 30 June 2020 due September
2020
----------------------------------------------------------------------------------- ----
Expected admission date:
28 June 2019
--------------------------------------------------------------------------------- ------
Name and address of Euronext
Growth Advisor
Davy Corporate Finance, Davy
House, 49 Dawson Street, Dublin
2
Name and address of broker
Arden Partners plc., 125 Old Broad Street, London, EC2N
1AR
-----------------------------------------------------------------------------------------
Other than in the case of a quoted Applicant, details of
where (postal or internet address) the admission document
will be available from, with a statement that this will
contain full details about the Applicant and the admission
of its securities
A copy of the admission document containing full details
about the applicant and the admission of its securities
will be available on the Company's website, www.vennlifesciences.com
-----------------------------------------------------------------------------------------
Date of notification
14 June 2019
--------------------------------------------------------------------------------- ------
New/update: New
--------------------------------------------------------------------------------- ------
This announcement has been issued through the Companies
Announcement Service of Euronext Dublin.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ISEGGUGGQUPBGGC
(END) Dow Jones Newswires
June 14, 2019 07:13 ET (11:13 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Sep 2023 to Sep 2024